医学
新辅助治疗
全身疗法
腺癌
辅助治疗
胰腺切除术
肿瘤科
胰腺癌
化疗
内科学
切除术
外科
癌症
乳腺癌
作者
Ryan C. Johnson,Paul H. McClelland,Syed A. Ahmad
标识
DOI:10.1016/j.suc.2024.04.002
摘要
While pancreatic adenocarcinoma requires surgical resection definitive cure, treatment paradigms are shifting toward a neoadjuvant approach to systemic therapy. Rationale is twofold: micro-metastatic disease is likely present in a majority of patients, reinforcing the importance of systemic therapy regardless of resectability; moreover, systemic therapy is well-tolerated and improves surgical outcomes when delivered preoperatively. Second, a neoadjuvant approach allows for selection of biology and patients most likely to benefit from potentially morbid surgery. This review examines the increasing body of evidence in support of empiric neoadjuvant therapy in pancreatic adenocarcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI